REGENXBIO Announces Presentation at Chardan's 6th Annual Genetic Medicines Conference

Rhea-AI Summary

REGENXBIO Inc. (Nasdaq: RGNX) announced its participation in Chardan's 6th Annual Genetic Medicines Conference on October 4, 2022, at 1:30 p.m. ET in New York, NY. The company will conduct a fireside chat, accessible via a live webcast on its website, with an archived version available for about 30 days post-event. REGENXBIO is recognized for its gene therapy advancements, utilizing its proprietary NAV Technology Platform comprising over 100 AAV vectors. The firm aims to progress five gene therapy programs into pivotal stages or commercial products by 2025.

Positive

• Participation in a reputable industry conference enhances visibility.
• Showcases commitment to advancing gene therapy through public engagement.

Negative

• None.

ROCKVILLE, Md., Sept. 27, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present in a fireside chat at Chardan's 6th Annual Genetic Medicines Conference on Tuesday, October 4th, 2022:

Chardan's 6^th Annual Genetic Medicines Conference
Date: Tuesday, October 4^th, 2022
Fireside chat: 1:30 p.m. ET
Location: Westin Grand Central, New York, NY

A live webcast of the fireside chat can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available in the Investors section of REGENXBIO's website for approximately 30 days following the presentation.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.

Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com 

Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-presentation-at-chardans-6th-annual-genetic-medicines-conference-301633825.html

SOURCE REGENXBIO Inc.

FAQ

What is the date of REGENXBIO's presentation at Chardan's conference?

REGENXBIO's presentation is scheduled for October 4, 2022.

What time does REGENXBIO's fireside chat start?

The fireside chat starts at 1:30 p.m. ET.

Where can I watch the REGENXBIO fireside chat?

The fireside chat can be watched live on REGENXBIO's website.

How long will the REGENXBIO webcast be available?

An archived replay of the webcast will be available for approximately 30 days.

What is REGENXBIO's '5x'25' strategy?

REGENXBIO aims to advance five gene therapy programs into pivotal stages or commercial products by 2025.